Literature DB >> 29262943

Vulvar cancer is not a disease of the elderly: Treatment and outcome at a tertiary referral centre in South Africa.

J L Butt1, M H Botha.   

Abstract

BACKGROUND: An increase in vulvar cancer in young women is attributed to infection with oncogenic human papillomavirus (HPV). South Africa (SA) has a high prevalence of HPV, and it was therefore hypothesised that women with vulvar cancer here would be younger than in high-income countries (HICs).
OBJECTIVE: To describe age, cancer stage, treatment and outcome of patients with vulvar cancer at a tertiary referral centre in SA.
METHODS: In a retrospective observational study, patient records of women diagnosed with vulvar cancer between 2001 and 2014 were reviewed and demographic and surgical details captured. Histology results of vulvar biopsies and resected specimens were checked for HPV changes, koilocytes and usual-type vulval intraepithelial neoplasia. Patients were restaged using the International Federation of Gynecology and Obstetrics (FIGO) 2009 staging system to allow for comparison of outcomes. Five-year disease-specific survival probability curves were generated using Kaplan-Meier analysis.
RESULTS: The mean age of the 180 patients in the study was 52.5 years. Those who had documented HPV changes on histological specimens had a mean age of 50.4 years. More than 50% of the patients had advanced-stage disease, and 62.7% were treated with primary surgery. Five-year disease-specific survival probabilities were similar to those reported in the literature.
CONCLUSIONS: Vulvar cancer should not be regarded as a disease of the elderly in SA, as women with vulvar cancer are 10 - 15 years younger than in HICs. A large proportion of patients present with advanced-stage disease. Health professionals should be alert to vulvar lesions, especially in women with abnormal Pap smears, to reduce the morbidity and mortality of this disease.

Entities:  

Year:  2017        PMID: 29262943     DOI: 10.7196/SAMJ.2017.v107i11.12497

Source DB:  PubMed          Journal:  S Afr Med J


  7 in total

1.  Vulvar cancer in Botswana in women with and without HIV infection: patterns of treatment and survival outcomes.

Authors:  Emily MacDuffie; Sruthi Sakamuri; Rebecca Luckett; Qiao Wang; Memory Bvochara-Nsingo; Barati Monare; Lisa Bazzett-Matabele; Thabo Moloi; Tlotlo Ralefala; Doreen Ramogola-Masire; Sanghyuk S Shin; Nicola M Zetola; Surbhi Grover
Journal:  Int J Gynecol Cancer       Date:  2021-09-07       Impact factor: 3.437

2.  High-risk human papillomavirus-associated vulvar neoplasia among women living with human immunodeficiency virus in Zambia.

Authors:  Fred Maate; Peter Julius; Stepfanie Siyumbwa; Leeya Pinder; Trevor Kaile; Mulindi Mwanahamuntu; Groesbeck Parham
Journal:  Afr J Lab Med       Date:  2022-05-12

3.  Vulvar cancer in Iran: Retrospective study over 20 years (1998-2018).

Authors:  Azamosadat Mousavi; Azadeh Yousefnezhad; Mitra Modarres-Gilani; Setareh Akhavan; Shahrzad Sheikh-Hasani
Journal:  J Family Med Prim Care       Date:  2019-04

Review 4.  Management of Advanced Squamous Cell Carcinoma of the Vulva.

Authors:  Linda J Rogers
Journal:  Cancers (Basel)       Date:  2021-12-30       Impact factor: 6.639

5.  Impact of a delayed diagnosis of vulvar cancer and its association with HIV infection: A 4-year review at a tertiary hospital in KwaZulu-Natal, South Africa.

Authors:  Ramakhosana S Hlapane; Thandekile L Khumalo; Bongumusa S Makhathini; Jagidesa Moodley
Journal:  South Afr J HIV Med       Date:  2021-09-08       Impact factor: 2.744

6.  Cancer of the vulva: 2021 update.

Authors:  Alexander B Olawaiye; Mauricio A Cuello; Linda J Rogers
Journal:  Int J Gynaecol Obstet       Date:  2021-10       Impact factor: 4.447

Review 7.  Management of Early-Stage Vulvar Cancer.

Authors:  Priscila Grecca Pedrão; Yasmin Medeiros Guimarães; Luani Rezende Godoy; Júlio César Possati-Resende; Adriane Cristina Bovo; Carlos Eduardo Mattos Cunha Andrade; Adhemar Longatto-Filho; Ricardo Dos Reis
Journal:  Cancers (Basel)       Date:  2022-08-29       Impact factor: 6.575

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.